Starling Oncology (STLNW) Cost of Revenue (2021 - 2026)

Starling Oncology (STLNW) has reported Cost of Revenue for 6 consecutive years, with $134.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 31.1% year-over-year to $134.1 million; the trailing twelve-month figure through Jun 2026 stood at $289.3 million (up 39.05% YoY), and the FY2025 full-year result was $220.6 million, up 18.02% from the prior year.
• Cost of Revenue climbed to $134.1 million in Q2 2026 per STLNW's latest filing, from $124.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $134.1 million in Q2 2026 and bottomed at -$86.5 million in Q4 2025.
• Historically, Cost of Revenue has averaged $50.5 million across 5 years, with a median of $45.7 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue sank 238.33% in 2024, then soared 119.9% in 2025.
• Over 5 years, Cost of Revenue stood at $38.4 million in 2022, then increased by 26.01% to $48.4 million in 2023, then tumbled by 238.33% to -$66.9 million in 2024, then retreated by 29.36% to -$86.5 million in 2025, then jumped by 254.97% to $134.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $134.1 million, $124.1 million, and -$86.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.